Vasanta Rao Nanduri1, Jon Pritchard, Gill Levitt, Adam W Glaser. 1. Department of Haematology/Oncology, Great Ormond Street Hospital for Children, London, and Yorkshire Regional Centre for Paediatric Oncology and Haematology, St James University Hospital, Leeds, UK. vasanta.nanduri@whht.nhs.uk
Abstract
BACKGROUND: Langerhans' cell histiocytosis, a clonal multisystem disorder, can affect children or adults resulting in long term sequelae. However, the overall morbidity for survivors has not been formally determined. PATIENTS AND METHODS: We performed a cross-sectional study of 40 unselected long term survivors of childhood multisystem Langerhans cell histiocytosis, involving clinical examination, health-related quality of life assessment, brain imaging, neuropsychometry, endocrine assessment, respiratory function tests and audiometry. A specific 'morbidity score' was devised to measure outcome. RESULTS: Seventy-five percent of patients had detectable long term sequelae, hypothalamic-pituitary dysfunction (50%), cognitive dysfunction (20%) and cerebellar involvement (17.5%) being the most common. Half had moderate to severe morbidity, and the worst-affected patients were unable to lead an independent adult life. Health-related quality of life, which correlated well with the morbidity score (p<0.001), was adversely affected in >50% of patients. CONCLUSION: Organ damage from multisystem Langerhans cell histiocytosis causes long term morbidity extending into adult life. Carefully planned, multidisciplinary follow up is essential to ensure early recognition of problems with appropriate interventions to reduce the impact on patients' 'quality of life'.
BACKGROUND: Langerhans' cell histiocytosis, a clonal multisystem disorder, can affect children or adults resulting in long term sequelae. However, the overall morbidity for survivors has not been formally determined. PATIENTS AND METHODS: We performed a cross-sectional study of 40 unselected long term survivors of childhood multisystem Langerhans cell histiocytosis, involving clinical examination, health-related quality of life assessment, brain imaging, neuropsychometry, endocrine assessment, respiratory function tests and audiometry. A specific 'morbidity score' was devised to measure outcome. RESULTS: Seventy-five percent of patients had detectable long term sequelae, hypothalamic-pituitary dysfunction (50%), cognitive dysfunction (20%) and cerebellar involvement (17.5%) being the most common. Half had moderate to severe morbidity, and the worst-affected patients were unable to lead an independent adult life. Health-related quality of life, which correlated well with the morbidity score (p<0.001), was adversely affected in >50% of patients. CONCLUSION: Organ damage from multisystem Langerhans cell histiocytosis causes long term morbidity extending into adult life. Carefully planned, multidisciplinary follow up is essential to ensure early recognition of problems with appropriate interventions to reduce the impact on patients' 'quality of life'.
Authors: Georgi Iskrov; Itziar Astigarraga; Rumen Stefanov; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Arrigo Schieppati; Domenica Taruscio; Márta Péntek; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore Journal: Eur J Health Econ Date: 2016-04-04
Authors: Jean-François Emile; Oussama Abla; Sylvie Fraitag; Annacarin Horne; Julien Haroche; Jean Donadieu; Luis Requena-Caballero; Michael B Jordan; Omar Abdel-Wahab; Carl E Allen; Frédéric Charlotte; Eli L Diamond; R Maarten Egeler; Alain Fischer; Juana Gil Herrera; Jan-Inge Henter; Filip Janku; Miriam Merad; Jennifer Picarsic; Carlos Rodriguez-Galindo; Barret J Rollins; Abdellatif Tazi; Robert Vassallo; Lawrence M Weiss Journal: Blood Date: 2016-03-10 Impact factor: 22.113
Authors: Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen Journal: Nat Rev Dis Primers Date: 2021-10-07 Impact factor: 65.038
Authors: Willemijn T Quispel; Janine A Stegehuis-Kamp; Laura Blijleven; Susy J Santos; Magda Lourda; Cor van den Bos; Astrid G S van Halteren; R Maarten Egeler Journal: Oncoimmunology Date: 2015-08-31 Impact factor: 8.110
Authors: Jean Donadieu; Islam Amine Larabi; Mathilde Tardieu; Johannes Visser; Caroline Hutter; Elena Sieni; Nabil Kabbara; Mohamed Barkaoui; Jean Miron; François Chalard; Paul Milne; Julien Haroche; Fleur Cohen; Zofia Hélias-Rodzewicz; Nicolas Simon; Mathilde Jehanne; Alexandra Kolenova; Anne Pagnier; Nathalie Aladjidi; Pascale Schneider; Geneviève Plat; Anne Lutun; Anne Sonntagbauer; Thomas Lehrnbecher; Alina Ferster; Viktoria Efremova; Martina Ahlmann; Laurence Blanc; James Nicholson; Anne Lambilliote; Houda Boudiaf; Andrej Lissat; Karel Svojgr; Fanette Bernard; Sarah Elitzur; Michal Golan; Dmitriy Evseev; Michael Maschan; Ahmed Idbaih; Olga Slater; Milen Minkov; Valerie Taly; Matthew Collin; Jean-Claude Alvarez; Jean-François Emile; Sébastien Héritier Journal: J Clin Oncol Date: 2019-09-12 Impact factor: 44.544
Authors: Riccardo Haupt; Milen Minkov; Itziar Astigarraga; Eva Schäfer; Vasanta Nanduri; Rima Jubran; R Maarten Egeler; Gritta Janka; Dragan Micic; Carlos Rodriguez-Galindo; Stefaan Van Gool; Johannes Visser; Sheila Weitzman; Jean Donadieu Journal: Pediatr Blood Cancer Date: 2012-10-25 Impact factor: 3.167